Cardiometabolic Risks of Blonanserin and Perospirone in the Management of Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

BACKGROUND: The present study aimed to evaluate cardiometabolic risks [weight gain, blood lipid levels (total cholesterol and triglycerides), blood glucose levels, hemoglobin A(1c) (HbA(1c)) levels, and corrected QT interval (QTc) prolongation] associated with the use of blonanserin and perospirone...

Descripción completa

Detalles Bibliográficos
Autores principales: Kishi, Taro, Matsuda, Yuki, Iwata, Nakao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913743/
https://www.ncbi.nlm.nih.gov/pubmed/24505373
http://dx.doi.org/10.1371/journal.pone.0088049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913743/
https://www.ncbi.nlm.nih.gov/pubmed/24505373
http://dx.doi.org/10.1371/journal.pone.0088049

Ejemplares similares